Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage IV Hodgkin lymphoma in Italy

Objectives: Advanced Hodgkin’s lymphoma (HL) is a rare severe neoplasm, significantly limiting the ability of patients to do daily activities among other impacts of the cancer. Many adult patients present with advanced stage disease (stages III/IV). This analysis investigates the cost-effectiveness...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Chiara Bini, Andrea Marcellusi, Francesco Saverio Mennini, Silvia Ripoli, Laura Fioravanti, Victoria Federico Paly, Alexa Molinari, Paolo Morelli, Stanimira Krotneva, Shujun Li
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	AboutScience Srl 2024-12-01
Schriftenreihe:	Global & Regional Health Technology Assessment
Schlagworte:	Brentuximab Vedotin Cost-Effectiveness Analysis Economic evaluation Hodgkin lymphoma
Online-Zugang:	https://journals.aboutscience.eu/index.php/grhta/article/view/3167
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!